Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: CPNE1 (ImmuneEditome ID:8904)

1. Gene summary of enriched editing regions for CPNE1

Gene summary

Gene information	Gene symbol	CPNE1
	Gene ID	8904
	GeneSynonyms	COPN1\|CPN1
	GeneCytomap	20q11.22
	GeneType	protein-coding
	GeneDescription	copine-1\|chromobindin 17\|copine I
	GeneModificationdate	20230329
	UniprotID	Q99829;B0QZ18;Q5JX61;E7ENH5;Q5JX57;Q5JX56;Q5JX53;Q5JX58;Q5JX45;A6PVH9;Q5JX55;Q5JX54;Q5JX52;F2Z2V0;Q5JX59;Q5JX44;E7EV27;Q5JX60
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr20:35629702-35630339:-	ENST00000483359.4	ENSG00000214078.10	CPNE1	ncRNA_intronic	AluJb,AluSx1,MIR	chr20:35629702-35630339:-.alignment
chr20:35629702-35630339:-	ENST00000483495.4	ENSG00000214078.10	CPNE1	ncRNA_intronic	AluJb,AluSx1,MIR	chr20:35629702-35630339:-.alignment
chr20:35634781-35634953:-	ENST00000483359.4	ENSG00000214078.10	CPNE1	ncRNA_intronic	AluJo	chr20:35634781-35634953:-.alignment

Top

2. Tumor-specific enriched editing regions for CPNE1

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events

cancer

Type

Boxplot

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

StageType

AnovaP

Boxplot

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events

cancer

TypeID

Pkm

Pcox_continuous

HR_continuous

KMPlot

Top

3. Enriched editing regions and immune related genes for CPNE1

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr20:35629702-35630339:-

ESCA

EER

ENSG00000108256,NUFIP2

-0.4588

2.3830e-04

2.2421e-07

-0.4355

ADAR;HNRNPL;U2AF2

T_cells_CD4_memory_resting

GSVA_HALLMARK_HYPOXIA

chr20:35629702-35630339:-

ESCA

EER

ENSG00000163364,LINC01116

0.3210

1.9693e-02

1.7679e-06

0.4049

ADAR;U2AF2

Macrophages_M1

GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION

chr20:35629702-35630339:-

ESCA

EER

ENSG00000108256,NUFIP2

-0.4588

2.3830e-04

2.2421e-07

-0.4355

ADAR;HNRNPL;U2AF2

T_cells_CD4_memory_resting

GSVA_HALLMARK_HYPOXIA

chr20:35629702-35630339:-

ESCA

EER

ENSG00000163364,LINC01116

0.3210

1.9693e-02

1.7679e-06

0.4049

ADAR;U2AF2

Macrophages_M1

GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION

More results

Top

4. Enriched editing regions and immune related splicing for CPNE1

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr20:35629702-35630339:-

ESCA

EER

ENSG00000025708.8

chr22

50526000:50526156:50526245:50526476

-0.3405

4.9568e-02

2.9750e-06

-0.4118

HNRNPL;U2AF2

TYMP

GSVA_HALLMARK_DNA_REPAIR

chr20:35629702-35630339:-

ESCA

EER

ENSG00000137343.13

chr6

30645858:30645974:30646066:30646109

-0.3912

1.3081e-02

1.3448e-06

-0.4121

ADAR;U2AF2

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_MTORC1_SIGNALING

ENSG00000214078.10,CPNE1

ESCA

EAG

ENSG00000137343.13

chr6

30645858:30645974:30646066:30646109

-0.3564

3.4398e-02

1.4503e-06

-0.4009

ACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CPSF6;CSTF2T;DDX3X;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_MTORC1_SIGNALING

chr20:35629702-35630339:-

ESCA

EER

ENSG00000184428.8

chr8

143309323:143309543:143310067:143310217

-0.4527

1.7571e-03

6.5577e-07

-0.4200

ADAR;HNRNPL;U2AF2

T_cells_CD4_memory_resting

GSVA_HALLMARK_MYC_TARGETS_V1

chr20:35629702-35630339:-

ESCA

EER

ENSG00000166012.10

chr11

93732243:93736751:93737063:93737239

-0.3746

2.5863e-02

1.3211e-06

-0.4094

ADAR;HNRNPL;U2AF2

T_cells_CD4_memory_resting

GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION

chr20:35629702-35630339:-

ESCA

EER

ENSG00000171345.9

chr17

41525190:41525273:41525368:41525445

-0.3648

1.8203e-02

4.8475e-06

-0.4052

ADAR;U2AF2

B_cells_naive

GSVA_HALLMARK_GLYCOLYSIS

chr20:35629702-35630339:-

ESCA

EER

ENSG00000144580.9

chr2

218592557:218592707:218593527:218593845

-0.3833

1.8588e-02

1.3194e-06

-0.4094

ADAR;HNRNPL;U2AF2

RQCD1

T_cells_CD4_memory_resting

GSVA_HALLMARK_MTORC1_SIGNALING

chr20:35629702-35630339:-

ESCA

EER

ENSG00000101150.13

chr20

63882718:63887605:63889189:63889238

-0.3568

3.3371e-02

9.4883e-07

-0.4144

ADAR;HNRNPL;U2AF2

T_cells_CD4_memory_resting

GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE

More results

Top

5. Enriched editing regions and immune infiltration for CPNE1

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
chr20:35629702-35630339:-	ACC	EER	Dendritic_cells_resting	1.3079e-03	0.6410
ENSG00000214078.10,CPNE1	ACC	EAG	Dendritic_cells_resting	1.8577e-03	0.6133
chr20:35629702-35630339:-	BLCA	EER	T_cells_CD8	3.3756e-02	0.1701
ENSG00000214078.10,CPNE1	BRCA	EAG	NK_cells_activated	3.3809e-03	-0.1332
chr20:35629702-35630339:-	CESC	EER	Monocytes	3.2920e-02	0.2104
chr20:35629702-35630339:-	COAD	EER	Eosinophils	2.5921e-04	0.2808
ENSG00000214078.10,CPNE1	COAD	EAG	Eosinophils	1.7678e-03	0.2416
chr20:35629702-35630339:-	ESCA	EER	T_cells_regulatory_(Tregs)	4.3858e-03	-0.2483
ENSG00000214078.10,CPNE1	ESCA	EAG	T_cells_regulatory_(Tregs)	6.9102e-03	-0.2298
chr20:35629702-35630339:-	GBM	EER	Monocytes	3.7164e-02	0.2018
ENSG00000214078.10,CPNE1	GBM	EAG	Monocytes	3.1000e-02	0.2068
chr20:35629702-35630339:-	HNSC	EER	B_cells_memory	1.0823e-02	0.2801
ENSG00000214078.10,CPNE1	HNSC	EAG	B_cells_memory	9.5849e-03	0.2779
chr20:35629702-35630339:-	KIRC	EER	Dendritic_cells_activated	3.1801e-03	0.2175
ENSG00000214078.10,CPNE1	KIRC	EAG	B_cells_memory	3.9683e-03	0.2097
ENSG00000214078.10,CPNE1	KIRP	EAG	T_cells_gamma_delta	9.4207e-03	-0.2342
chr20:35629702-35630339:-	LAML	EER	B_cells_naive	1.0128e-02	-0.3033
chr20:35629702-35630339:-	LUAD	EER	Eosinophils	6.5952e-04	0.2087
ENSG00000214078.10,CPNE1	LUAD	EAG	Macrophages_M1	1.7143e-02	0.1461
chr20:35629702-35630339:-	OV	EER	Mast_cells_activated	3.9063e-02	0.1468
chr20:35629702-35630339:-	PAAD	EER	Macrophages_M0	2.0463e-02	0.2526
ENSG00000214078.10,CPNE1	PAAD	EAG	T_cells_follicular_helper	1.5223e-02	-0.2595
chr20:35629702-35630339:-	PCPG	EER	NK_cells_resting	1.5875e-02	0.3154
ENSG00000214078.10,CPNE1	PCPG	EAG	NK_cells_resting	1.1492e-02	0.3269
chr20:35629702-35630339:-	PRAD	EER	T_cells_follicular_helper	1.3208e-02	-0.2389
ENSG00000214078.10,CPNE1	PRAD	EAG	NK_cells_resting	4.8850e-02	0.1858
chr20:35629702-35630339:-	READ	EER	Plasma_cells	3.5603e-02	0.2481
ENSG00000214078.10,CPNE1	READ	EAG	Plasma_cells	3.4368e-02	0.2498
ENSG00000214078.10,CPNE1	STAD	EAG	Macrophages_M0	2.3611e-02	-0.1533
chr20:35629702-35630339:-	TGCT	EER	Macrophages_M1	3.0932e-03	0.4268
ENSG00000214078.10,CPNE1	TGCT	EAG	Macrophages_M1	8.4459e-03	0.3799
chr20:35629702-35630339:-	UCEC	EER	T_cells_CD8	4.7657e-03	0.4374
ENSG00000214078.10,CPNE1	UCEC	EAG	Dendritic_cells_activated	2.2843e-02	0.3247
chr20:35629702-35630339:-	UCS	EER	Macrophages_M0	3.7040e-02	0.4370

Top

6. Enriched editing regions and immune gene sets for CPNE1

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events

cancer

Type

E2M_P

Boxplot

CorP

CorR

CorrelationPlot

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events	cancer	Type	Buffa_P	Buffa_R	Ragnum_P	Ragnum_R	Winter_P	Winter_R	HALLMARK_P	HALLMARK_R	CorrelationPlot
chr20:35629702-35630339:-	ESCA	EER	3.8738e-05	0.3526	6.4491e-03	0.2378	2.8352e-04	0.3133	1.3913e-02	0.2153

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
chr20:35629702-35630339:-	ACC	GSVA_HALLMARK_INFLAMMATORY_RESPONSE	EER	1.8381e-02	0.4979
ENSG00000214078.10,CPNE1	ACC	GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE	EAG	1.8353e-02	-0.4873
chr20:35629702-35630339:-	BLCA	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EER	3.2163e-02	0.1716
ENSG00000214078.10,CPNE1	BRCA	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EAG	2.0670e-02	0.1054
chr20:35629702-35630339:-	BRCA	GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE	EER	3.3049e-02	0.0986
chr20:35629702-35630339:-	CESC	GSVA_HALLMARK_ADIPOGENESIS	EER	1.7082e-02	0.2346
ENSG00000214078.10,CPNE1	COAD	GSVA_HALLMARK_E2F_TARGETS	EAG	6.4877e-03	-0.2111
chr20:35629702-35630339:-	COAD	GSVA_HALLMARK_E2F_TARGETS	EER	4.5047e-03	-0.2201
chr20:35629702-35630339:-	ESCA	GSVA_HALLMARK_MTORC1_SIGNALING	EER	6.9625e-04	0.2937
ENSG00000214078.10,CPNE1	ESCA	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	1.9909e-04	0.3127
ENSG00000214078.10,CPNE1	GBM	GSVA_HALLMARK_PEROXISOME	EAG	7.9241e-04	0.3167
chr20:35629702-35630339:-	GBM	GSVA_HALLMARK_BILE_ACID_METABOLISM	EER	7.9706e-04	0.3194
ENSG00000214078.10,CPNE1	HNSC	GSVA_HALLMARK_COMPLEMENT	EAG	3.0631e-03	0.3157
chr20:35629702-35630339:-	HNSC	GSVA_HALLMARK_COMPLEMENT	EER	6.7421e-03	0.2970
ENSG00000214078.10,CPNE1	KIRC	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EAG	4.4021e-04	0.2545
chr20:35629702-35630339:-	KIRC	GSVA_HALLMARK_UV_RESPONSE_UP	EER	1.1522e-03	0.2391
chr20:35629702-35630339:-	KIRP	GSVA_HALLMARK_PEROXISOME	EER	8.4428e-05	0.3598
ENSG00000214078.10,CPNE1	KIRP	GSVA_HALLMARK_PEROXISOME	EAG	1.8871e-05	0.3768
chr20:35629702-35630339:-	LGG	GSVA_HALLMARK_ADIPOGENESIS	EER	3.4235e-03	0.1779
ENSG00000214078.10,CPNE1	LGG	GSVA_HALLMARK_TGF_BETA_SIGNALING	EAG	1.4142e-03	0.1919
chr20:35629702-35630339:-	LIHC	GSVA_HALLMARK_ANDROGEN_RESPONSE	EER	1.4606e-02	0.4344
ENSG00000214078.10,CPNE1	LIHC	GSVA_HALLMARK_ANDROGEN_RESPONSE	EAG	4.6326e-02	0.3342
chr20:35629702-35630339:-	LUAD	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	1.1707e-03	0.1991
ENSG00000214078.10,CPNE1	LUAD	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	8.9385e-04	0.2025
chr20:35629702-35630339:-	LUSC	GSVA_HALLMARK_PROTEIN_SECRETION	EER	1.1403e-04	0.2137
ENSG00000214078.10,CPNE1	LUSC	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	2.3966e-03	0.1679
chr20:35629702-35630339:-	OV	GSVA_HALLMARK_COAGULATION	EER	3.7596e-04	0.2503
ENSG00000214078.10,CPNE1	OV	GSVA_HALLMARK_COAGULATION	EAG	3.7034e-03	0.2014
chr20:35629702-35630339:-	PAAD	GSVA_HALLMARK_FATTY_ACID_METABOLISM	EER	9.2536e-03	0.2824
chr20:35629702-35630339:-	PRAD	GSVA_HALLMARK_BILE_ACID_METABOLISM	EER	3.9249e-03	0.2766
ENSG00000214078.10,CPNE1	PRAD	GSVA_HALLMARK_BILE_ACID_METABOLISM	EAG	4.8498e-03	0.2632
chr20:35629702-35630339:-	READ	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EER	8.3442e-03	0.3086
ENSG00000214078.10,CPNE1	READ	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EAG	4.5966e-03	0.3303
chr20:35629702-35630339:-	SARC	GSVA_HALLMARK_BILE_ACID_METABOLISM	EER	3.3498e-02	-0.2601
ENSG00000214078.10,CPNE1	SARC	GSVA_HALLMARK_TGF_BETA_SIGNALING	EAG	1.1693e-02	0.2917
chr20:35629702-35630339:-	SKCM	GSVA_HALLMARK_PROTEIN_SECRETION	EER	5.5239e-03	0.2113
ENSG00000214078.10,CPNE1	SKCM	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	1.0746e-02	0.1924
chr20:35629702-35630339:-	STAD	GSVA_HALLMARK_APOPTOSIS	EER	3.7207e-04	0.2549
ENSG00000214078.10,CPNE1	STAD	GSVA_HALLMARK_XENOBIOTIC_METABOLISM	EAG	7.5352e-05	0.2648
chr20:35629702-35630339:-	TGCT	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EER	1.7541e-02	-0.3487
ENSG00000214078.10,CPNE1	TGCT	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EAG	1.1474e-02	-0.3657
chr20:35629702-35630339:-	THCA	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EER	1.4514e-02	0.1701
chr20:35629702-35630339:-	THYM	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EER	2.3876e-03	0.4563
ENSG00000214078.10,CPNE1	THYM	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EAG	9.8423e-03	0.3939
chr20:35629702-35630339:-	UCEC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	9.3451e-03	0.4060
ENSG00000214078.10,CPNE1	UCS	GSVA_HALLMARK_KRAS_SIGNALING_DN	EAG	2.0598e-02	-0.4515
chr20:35629702-35630339:-	UCS	GSVA_HALLMARK_FATTY_ACID_METABOLISM	EER	2.6871e-02	0.4609

Top

7. Enriched editing regions and drugs for CPNE1

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
chr20:35629702-35630339:-	BLCA	AZD.2281	EER	4.1318e-05	-0.3221
ENSG00000214078.10,CPNE1	BLCA	ABT.263	EAG	5.1119e-03	-0.2132
chr20:35629702-35630339:-	BRCA	BIBW2992	EER	1.7143e-02	-0.1101
ENSG00000214078.10,CPNE1	BRCA	GW843682X	EAG	2.2436e-02	0.1040
ENSG00000214078.10,CPNE1	COAD	JNK.Inhibitor.VIII	EAG	1.5080e-02	0.1889
chr20:35629702-35630339:-	COAD	BMS.708163	EER	1.3567e-02	-0.1918
chr20:35629702-35630339:-	ESCA	Docetaxel	EER	9.8157e-04	-0.2858
ENSG00000214078.10,CPNE1	ESCA	BMS.509744	EAG	1.3742e-03	-0.2708
chr20:35629702-35630339:-	GBM	Bosutinib	EER	8.6462e-04	0.3174
ENSG00000214078.10,CPNE1	GBM	Bosutinib	EAG	1.0234e-03	0.3103
ENSG00000214078.10,CPNE1	HNSC	AS601245	EAG	2.2440e-02	-0.2460
chr20:35629702-35630339:-	HNSC	DMOG	EER	3.4791e-02	-0.2335
chr20:35629702-35630339:-	KIRC	JNK.9L	EER	5.2829e-04	0.2544
ENSG00000214078.10,CPNE1	KIRC	JNK.Inhibitor.VIII	EAG	8.5184e-03	0.1919
chr20:35629702-35630339:-	KIRP	Cisplatin	EER	6.6560e-03	-0.2528
ENSG00000214078.10,CPNE1	KIRP	FH535	EAG	2.3541e-03	-0.2729
chr20:35629702-35630339:-	LAML	BI.2536	EER	3.4598e-02	0.2512
chr20:35629702-35630339:-	LGG	BMS.509744	EER	1.9687e-02	-0.1421
ENSG00000214078.10,CPNE1	LGG	MG.132	EAG	2.3478e-02	-0.1369
chr20:35629702-35630339:-	LIHC	Cyclopamine	EER	1.0196e-02	-0.4774
ENSG00000214078.10,CPNE1	LIHC	Cyclopamine	EAG	6.0391e-03	-0.4748
chr20:35629702-35630339:-	LUAD	AZD8055	EER	1.3164e-03	0.1971
ENSG00000214078.10,CPNE1	LUAD	AZD8055	EAG	2.0020e-03	0.1886
ENSG00000214078.10,CPNE1	LUSC	CI.1040	EAG	7.7316e-03	-0.1475
chr20:35629702-35630339:-	LUSC	CI.1040	EER	1.6274e-03	-0.1752
chr20:35629702-35630339:-	OV	AZ628	EER	4.0370e-05	-0.2874
ENSG00000214078.10,CPNE1	OV	Bicalutamide	EAG	8.7517e-04	-0.2301
ENSG00000214078.10,CPNE1	PAAD	FH535	EAG	4.1212e-02	-0.2206
chr20:35629702-35630339:-	PAAD	AUY922	EER	2.5504e-02	-0.2437
chr20:35629702-35630339:-	PCPG	Bosutinib	EER	3.3309e-03	0.3792
ENSG00000214078.10,CPNE1	PCPG	Bosutinib	EAG	1.7041e-02	0.3096
chr20:35629702-35630339:-	PRAD	Bleomycin	EER	5.6811e-03	0.2657
ENSG00000214078.10,CPNE1	PRAD	Lenalidomide	EAG	2.4619e-02	0.2114
ENSG00000214078.10,CPNE1	READ	KIN001.135	EAG	2.1175e-02	-0.2713
chr20:35629702-35630339:-	READ	Docetaxel	EER	1.4913e-02	-0.2859
chr20:35629702-35630339:-	SARC	Bicalutamide	EER	2.9741e-02	-0.2657
ENSG00000214078.10,CPNE1	SARC	Bicalutamide	EAG	3.1184e-02	-0.2507
chr20:35629702-35630339:-	SKCM	Cytarabine	EER	1.6168e-03	0.2394
ENSG00000214078.10,CPNE1	SKCM	Cytarabine	EAG	3.0313e-03	0.2229
ENSG00000214078.10,CPNE1	STAD	Metformin	EAG	9.4545e-04	-0.2224
chr20:35629702-35630339:-	STAD	BMS.509744	EER	1.3884e-03	-0.2297
chr20:35629702-35630339:-	TGCT	BMS.754807	EER	9.8765e-03	0.3767
ENSG00000214078.10,CPNE1	TGCT	BMS.754807	EAG	7.1150e-03	0.3876
ENSG00000214078.10,CPNE1	UCEC	EHT.1864	EAG	2.7002e-02	0.3159
chr20:35629702-35630339:-	UCEC	Erlotinib	EER	1.8209e-03	-0.4778
ENSG00000214078.10,CPNE1	UCS	Gefitinib	EAG	2.9619e-02	-0.4269
chr20:35629702-35630339:-	UCS	GDC.0449	EER	3.9781e-04	-0.6761

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType